Broadway Wealth Solutions Inc. Purchases New Stake in Zoetis Inc. (NYSE:ZTS)

Broadway Wealth Solutions Inc. acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 1,673 shares of the company's stock, valued at approximately $273,000.

Several other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC raised its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its position in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares during the period. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after buying an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis during the fourth quarter worth $58,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Remove Ads

Zoetis Price Performance

Shares of NYSE:ZTS traded down $0.99 on Tuesday, hitting $163.66. The company had a trading volume of 643,941 shares, compared to its average volume of 2,975,382. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market cap of $73.29 billion, a PE ratio of 29.92, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The business has a 50 day moving average of $166.37 and a 200 day moving average of $174.26.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 target price on the stock. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.